Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5951-5960 Newer>

The Motley Fool October 19, 2009 Rich Smith	This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase.
The Motley Fool October 19, 2009 Brian Orelli	Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool October 16, 2009 Robert Steyer	Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
BusinessWeek October 15, 2009 Jeff Gerth	The Spectre Haunting GE Many MRI patients are injected with a GE dye to enhance images. If they have weak kidneys, they might develop a rare and sometimes fatal disease.
BusinessWeek October 15, 2009	Healthy Business In May, GE launched the "Healthymagination" campaign to promote its growing medical division. Here are some vital statistics.
The Motley Fool October 15, 2009 Brian Orelli	An Ode to Wyeth Pfizer weds Wyeth today and the WYE ticker will be gone forever.
The Motley Fool October 15, 2009 Robert Steyer	Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.
The Motley Fool October 15, 2009 Brian Orelli	This Partnership Will Go No Further Wyeth and Progenics call it quits.
<Older 5951-5960 Newer> Return to current articles.